


Defeat Osteosarcoma

21 April 2011 — 01:04 { [Posts RSS](#) } { [Comments RSS](#) }

This site is dedicated to curing osteosarcoma



[HOME](#) [DEFEAT OSTEOSARCOMA](#) [SUPPORT GROUPS AND DONATIONS](#) [FLOURIDE AND OSTEOSARCOMA](#)

[BEST OSTEOSARCOMA TREATMENT CENTERS IN THE UNITED STATES](#) [ABOUT](#) [RESEARCH CENTERS](#)

Sandia and UNM lead effort to destroy cancers

Posted 18 Apr 2011 in [NanoTechnology](#)

No Comments

WEBWIRE – Monday, April 18, 2011

Boosting medicine with nanotechnology strengthens drug cocktail many times over ALBUQUERQUE, N.M. — Melding nanotechnology and medical research, Sandia National Laboratories, the University of New Mexico, and the UNM Cancer Research and Treatment Center have produced an effective strategy that uses nanoparticles to blast cancerous cells with a mélange of killer drugs.

In the cover article of the May issue of Nature Materials, available online April 17, the researchers describe silica nanoparticles about 150 nanometers in diameter as honeycombed with cavities that can store large amounts and varieties of drugs.

“The enormous capacity of the nanoporous core, with its high surface area, combined with the improved targeting of an encapsulating lipid bilayer [called a liposome], permit a single ‘protocell’ loaded with a drug cocktail to kill a drug-resistant cancer cell,” says Sandia researcher and UNM professor Jeff Brinker, the principal investigator.

“That’s a millionfold increase in efficiency over comparable methods employing liposomes alone — without nanoparticles — as drug carriers.”

The nanoparticles and the surrounding cell-like membranes formed from liposomes together become the combination referred to as a protocell: the membrane seals in the deadly cargo and is modified with molecules (peptides) that bind specifically to receptors overexpressed on the cancer cell’s surface. (Too many receptors is one signal the cell is cancerous.) The nanoparticles provide stability to the supported membrane and contain and release the therapeutic cargo within the cell.

A current Food and Drug Administration-approved nanoparticle delivery strategy is to use liposomes themselves to contain and deliver the cargo.

In a head-to-head comparison of targeted liposomes and protocells with identical membrane and peptide compositions, Brinker and colleagues report that the greater cargo capacity, stability and targeting efficacy of protocells leads to many times greater cytotoxicity [destruction] directed specifically toward human liver cancer cells. Another advantage to protocells over liposomes alone, says lead author Carlee Ashley, a Harry S. Truman post-doctoral fellow at Sandia’s California site in Livermore, is that liposomes used as carriers need specialized loading strategies that make the process more difficult.

“We’ve demonstrated we can just soak nanoparticles to load them with unique drug combinations needed for personalized medicine. They effectively encapsulate toxins as well as siRNA [ribonucleic acid] that silence expressions of proteins.”

Latest Posts

[VEGFA gene amplification associated with poor prognosis in osteosarcoma](#)

Posted April 18, 2011 Yang J. Cancer. 2011;doi:10.1002/cncr.26116. Results from an analysis of tissue sections from 58 patients with osteosarcoma ...

[Protect cancer research funding](#)

By Jari Johnston-Allen April 18, 2011 The National Cancer Institute recently released a report showing nearly 12 million Americans are ...

[Man’s best friend: A joint tumor marker in man and dog](#)

Published: Monday, April 18, 2011 – 09:05 in Biology & Nature Despite steadily improving methods for its diagnosis and treatment, ...

[Decoding tumors in search of more effective cancer treatments](#)

By Amber Dance, Special to the Los Angeles Times April 18, 2011 Cancer cells are riddled with genetic errors, and each ...

[Sandia and UNM lead effort to destroy cancers](#)

WEBWIRE – Monday, April 18, 2011 Boosting medicine with nanotechnology strengthens drug cocktail many times over ALBUQUERQUE, N.M. — Melding ...

RNA, the biological messenger that tells cells which proteins to manufacture, in this case is used to silence the cellular factory, a way of causing apoptosis or cell death. "Si" is short for "silence." The lipids also serve as a shield that restricts toxic chemotherapy drugs from leaking from the nanoparticle until the protocell binds to and takes hold within the cancer cell. This means that few poisons leak into the system of the human host, if the protocells find no cancer cells. This cloaking mitigates toxic side effects expected from conventional chemotherapy. Instead, the particles — crafted small enough to float under the radar of the liver and other cleansing organs — can circulate harmlessly for days or weeks, depending on their engineered size, seeking their prey.

A library of phages — viruses that attack bacteria — was created at UNM's nationally accredited cancer center by collaborator David Peabody. This permitted researchers to expose the phages to a group of cancerous cells and normal cells, allowing identification of peptides that bind specifically to cancer cells but not normal cells.

"Proteins modified with a targeting peptide that binds to a particular carcinoma exhibit a 10,000-fold greater affinity for that cancer than for other unrelated cells," Ashley said.

Boosting medicine with nanotechnology strengthens drug cocktail many times over Brinker adds, "A key feature of our protocell is that its fluid bilayer allows high-affinity binding with just a few of these peptides overall. This reduces nonspecific binding and immune response."

The method is being tested on human cancer cells in vivo, and will shortly be tested on mouse tumors at UNM's cancer center.

The researchers continue to optimize the size of the porous silica particle, which is formed by aerosolizing a precursor solution. The porous nanoparticle fabrication process — called evaporation-induced self-assembly, and pioneered in the Brinker lab — produces particles from 50 nanometers to several microns in diameter. Particle sizes between 50 and 150 nanometers in diameter are ideal for maximizing circulation and uptake into cancer cells, so the particles are preselected by size before their formation into protocells.

"Their overall dimensions determine how widely they'll be distributed in the bloodstream," Brinker said. "We're altering our synthesis to favor the smaller sizes."

Also of importance to the circulation time of the particle are its electrical charge and hydrophobicity [avoidance of water], which can improve or detract from its ability to remain free of unwanted molecular or energetic entanglements. The method may be commercially available in five years, researchers estimate. Brinker is a Sandia Fellow and UNM Regent's and Distinguished Professor of Chemical and Nuclear Engineering and member of UNM's cancer center.

Other institutions involved in the research include the University of California Davis, and the University of Waterloo in Canada.

Funding was provided by the National Cancer Institute (NCI), the National Science Foundation, the Department of Energy's Basic Energy Sciences program, the Air Force Office of Scientific Research, and Sandia's Laboratory Directed Research and Development office.

The work is the first to show targeted delivery of nanoparticles to cancers that is supported in part by a grant from NCI's Alliance for Nanotechnology in Cancer. Sandia National Laboratories is a multiprogram laboratory operated and managed by Sandia Corporation, a wholly owned subsidiary of Lockheed Martin Corporation, for the U.S. Department of Energy's National Nuclear Security Administration. With main facilities in Albuquerque, N.M., and Livermore, Calif., Sandia has major R&D responsibilities in national security, energy and environmental technologies, and economic competitiveness.

Posted 18 Apr 2011 in [NanoTechnology](#)
by James Street



Recent Comments

[James Street](#)

This study has been neglected too long. Human trials should begin immediately.



[jlb](#)

Regarding the US oncologists treatment of cancer, one must understand that the universities are funded by the drug companies therefore



[admin](#)

The sad thing about the fluoride problem is not simply what it represents in itself, but what it represents as



[Philip](#)

The National Academy of Sciences did a thorough review on fluoride in 2006. They documented numerous deleterious effects of fluoride



[previous](#)

[Did everyday chemicals cause my tumor?](#)

[next](#)

[Decoding tumors in search of more effective cancer treatments](#)

Comments are closed.

Useful Tags

[artificial bones](#) [bone implants](#) [bone repair](#) [CAM](#) [cancer](#)
[funds](#) **[cancer research](#)** [cancer research](#)
[underfunded](#) [cisplatin](#) [cisplatin resistant tumors](#) [colon cancer](#)
[colonoscopy](#) [dogs](#) [endostatin reduces angiogenesis in](#)
[osteosarcoma](#) [flouridation](#) **[flouride](#)** [folic acid](#) [fusilev](#)
[gamma-tocotrienol](#) [genetic markers](#) [iRGD peptide](#) [Life](#)
[Extension Foundation](#) [metformin](#) [methotraxate](#)
[nanotechnology](#) [new bones](#) [new osteosarcoma](#)
[treatments](#) **[osteosarcoma](#)**
[osteosarcoma diagnostic test](#) [osteosarcoma follow-up](#)
[testing](#) [osteosarcoma metastases](#) [osteosarcoma recurrence](#)
[osteosarcoma research](#) [peptide chain](#) **[personalized](#)**
[cancer treatment](#) [personalized osteosarcoma](#)
[treatment](#) **[prostate cancer](#)** [SMO](#) [SMO](#)
[inactivation](#) [So many needless cancer deaths](#) [Spectrum](#)
[Pharmaceuticals](#) [vitamin E analog](#) [water flouridation](#) [William](#)
[Faloon](#) [zoledronic acid](#) [zoledronic acid and osteosarcoma](#)

Categories

[Age and osteosarcoma](#) [Alcohol](#) (1)
(3) [Alternative Therapies](#)
(39)
[Antiangiogenesis](#) (16) [antiangiogenesis](#) (11)
[antiinflammatory](#) (5) [Antioxidants](#) (11)
[Apoptosis](#) (2) [Artificial Knees and](#)
[implants](#) (3)
[Artificial limbs](#) (8) [Avastin](#) (1)
[Avastin](#) (2) [Bacteria](#) (4)
[Bacteria](#) (1) [Big Pharma](#) (8)
[Big Pharma](#) (15) [bone biopsy](#) (1)
[bone biopsy](#) (2) [Bone repair](#) (12)
[Book Reviews](#) (3) [Breast Cancer](#) (8)
[Cachexia](#) (2) [Cancer Journals](#) (2)
[Cannabis](#) (5) [Carcinogens](#) (2)
[Cat osteosarcoma](#) (2) [Chemotherapy](#) (32)
[Circulating Tumor Cells](#) [Clinical Trials](#) (9)
(8) [Colon Cancer](#) (9)
[Combination](#) [Complementary](#)
[Treatments](#) (13) [Therapy](#) (17)
[Cost](#) (5) [CURCUMIN](#) (2)
[Diagnostic](#) (39) [Diet and Prostate](#)
[Cancer](#) (23)
[Dog Osteosarcoma](#) [Drug](#) (34)
(23) [Drug Companies](#) (17)
[Drug Interactions](#) (4) [Drug Resistance](#) (1)
[Drug Testing](#) (23) [Educational](#) (38)
[Epigenetics](#) (3) [Ethics of Science](#) (12)
[Etiology and cause of](#) [experimental](#)
[osteosarcoma](#) (20) [treatments](#) (18)
[Fasting](#) (1) [Finance and Politics of](#)
[cancer research and](#)
[treatment](#) (86)
[Flouridation and](#) [Follow up Treatment](#)
[osteosarcoma](#) (8) (10)
[Foundations](#) (10) [Fraud](#) (8)
[General Cancer](#) [genetic](#) (9)
[Research](#) (78) [genetic research](#) (48)
[genetic research](#) (106) [Glucose](#) (4)
[Hospital Safety](#) (1) [Human osteosarcoma](#)
[research](#) (32)
[Hyperthermia](#) (4) [Hypoxia](#) (2)
[Imaging](#) (12) [Imaging](#) (2)
[Immune System](#) (24) [Individualized treatment](#)
(9)
[Inflammation](#) (4) [Interferon](#) (1)
[Kanzius Machine](#) (2) [Legal](#) (9)
[Legal Issues](#) (2) [Life Extension](#)
[Foundation](#) (3)
[Light-sensitive](#) (1) [Limb and organ](#)
[Regeneration](#) (3)
[Local Recurrence](#) (19) [Lung Metastases](#) (34)
[Mathematical Modelling](#) [Melanoma](#) (1)
(5) [Melanoma](#) (2)

Metastases (62)	metastases (24)
MicroRNA (4)	Mitochondria (1)
Molecular (35)	Molecular
	Osteosarcoma Studies
	(41)
Mouse Osteosarcoma	NanoTechnology (23)
Studies (15)	Natural Therapies (55)
Nutrition and Cancer	Obesity (4)
(57)	Osteosarcoma clinical
	trials (3)
Osteosarcoma	Osteosarcoma
Outcomes (11)	Research (39)
Osteosarcoma	Osteosarcoma
Specialists (2)	Treatment Centers (7)
Personalized (10)	Physics and
	Engineering (5)
Politics and Finance of	Prevention (30)
Child Cancer research	Prostate Cancer (72)
(3)	Proteomics (9)
Proteomics (9)	Proton Beam (6)
Proton Beam (3)	Radiation (4)
Radiation (4)	Radio Frequency RF
	(2)
Research Centers (14)	RNAi (1)
Salmonella typhimurium	STAT3 (2)
(2)	Stem Cell Research
	(28)
Stem Cell Research (3)	Stress (2)
Stromal (2)	Surgery (12)
Targeted Cancer	Thermal Tumor
Therapy (15)	Ablation (1)
Thoracic Surgery (4)	Top Page (1)
Tumor biomarkers (1)	Uncategorized (3)
Understanding Cancer	Vaccine (15)
(38)	vaccine (2)
Vaccine Studies (14)	Virus (3)
virus studies (7)	Vitamin D (6)
Vitamins and	Warburg (1)
Supplements (17)	